AdvaMed Weighs FDA Draft Guidance on HDE Program
December 28, 2018 In comments released in August 2018, AdvaMed said it disagreed with FDA’s position on what should be considered valid economic factors to determining profit eligibility, while also taking issue with a lack of clarity that randomized controlled trials are not necessary to demonstrate probable benefit. “To demonstrate probable benefit, standard of care … Read more